Alexandra Smith

A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial

S. Bach, M. Teo, D. Sebag‐Montefiore, 2022, BMJ Open.

Are we over-treating with checkpoint inhibitors?

P. Corrie, S. Danson, H. Marshall, 2019, British Journal of Cancer.

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

A. Pettitt, C. Fegan, C. Dearden, 2007 .

The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma

R. Plummer, F. Gallagher, J. Bestall, 2021, BMC cancer.

Eradication of minimal residual disease improves overall and progression‐free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation

W. Gregory, C. Fegan, G. Follows, 2017, British journal of haematology.

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

A. Pettitt, J. Radford, C. Fegan, 2011, British journal of haematology.

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuate

W. Gregory, R. Longo, J. O’Dwyer, 2017, Health technology assessment.